Last reviewed · How we verify

POLYSAN Scientific & Technological Pharmaceutical Company — Portfolio Competitive Intelligence Brief

POLYSAN Scientific & Technological Pharmaceutical Company pipeline: 1 marketed, 0 filed, 5 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 5 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Ringer's Solution Ringer's Solution marketed Crystalloid IV fluid / Electrolyte replacement solution Critical Care / Fluid & Electrolyte Management
Remaxol Remaxol phase 3 Other
Placebo enteric-coated tablet Placebo enteric-coated tablet phase 3
Cytoflavin® enteric-coated tablet Cytoflavin® enteric-coated tablet phase 3 Metabolic enhancer / Antioxidant combination Neurology / Metabolic disorders
Cytoflavin® solution Cytoflavin® solution phase 3 Metabolic activator / Antioxidant combination Neurology / Critical Care
Cycloferon Cycloferon phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for POLYSAN Scientific & Technological Pharmaceutical Company:

Cite this brief

Drug Landscape (2026). POLYSAN Scientific & Technological Pharmaceutical Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/polysan-scientific-technological-pharmaceutical-company. Accessed 2026-05-16.

Related